The global artificial pancreas device systems (APDS) market size reached US$ 2.33 billion in 2023. Looking forward, the market is projected to reach US$ 5.80 billion by 2032, exhibiting a growth rate (CAGR) of 10.62% during 2023-2032.
APDS refers to a closed-loop or automated insulin delivery system that manages blood glucose levels by regulating the production of insulin. It consists of a continuous glucose monitor (CGM), a subcutaneous insulin infusion pump and a controller that links the monitor with the pump. It runs a complex algorithm that determines the adequate levels of insulin and time of delivery based on the evaluation of real-time glucose readings. It is primarily used to minimize the risks of extreme fluctuations of glucose levels in the body.
The increasing prevalence of pancreatic cancer, pancreatitis and other chronic ailments is one of the key factors driving the growth of the market. Furthermore, the growing occurrence of diabetes and obesity, due to age-related factors, physical inactivity and unhealthy dietary patterns, is also contributing to the widespread adoption of APDS across the globe. The rising demand for efficient diabetes monitoring and minimally invasive (MI) drug delivery systems is also providing a boost to the market growth. APDS automatically monitors the glucose levels and administers doses of insulin throughout the day in controlled amounts.
Various technological innovations, including the development of software-based wireless systems that are integrated with automated controls, are further contributing to the market growth. Moreover, regulatory bodies and governments of various nations are significantly investing in research and development (R&D) for the improvement of healthcare infrastructure across the globe. For instance, the Food and Drug Association (US FDA) in the United States is approving an increasing number of new and innovative products, which is creating a positive outlook for the market in the country.
APDS refers to a closed-loop or automated insulin delivery system that manages blood glucose levels by regulating the production of insulin. It consists of a continuous glucose monitor (CGM), a subcutaneous insulin infusion pump and a controller that links the monitor with the pump. It runs a complex algorithm that determines the adequate levels of insulin and time of delivery based on the evaluation of real-time glucose readings. It is primarily used to minimize the risks of extreme fluctuations of glucose levels in the body.
The increasing prevalence of pancreatic cancer, pancreatitis and other chronic ailments is one of the key factors driving the growth of the market. Furthermore, the growing occurrence of diabetes and obesity, due to age-related factors, physical inactivity and unhealthy dietary patterns, is also contributing to the widespread adoption of APDS across the globe. The rising demand for efficient diabetes monitoring and minimally invasive (MI) drug delivery systems is also providing a boost to the market growth. APDS automatically monitors the glucose levels and administers doses of insulin throughout the day in controlled amounts.
Various technological innovations, including the development of software-based wireless systems that are integrated with automated controls, are further contributing to the market growth. Moreover, regulatory bodies and governments of various nations are significantly investing in research and development (R&D) for the improvement of healthcare infrastructure across the globe. For instance, the Food and Drug Association (US FDA) in the United States is approving an increasing number of new and innovative products, which is creating a positive outlook for the market in the country.
Key Market Segmentation
This report provides an analysis of the key trends in each sub-segment of the global artificial pancreas device systems (APDS) market report, along with forecasts at the global, regional and country level from 2024-2032. The report has categorized the market based on device type, treatment type and end-user.Breakup by Device Type:
- Threshold Suspend Device Systems
- Control-to-Range Systems
- Control-to-Target Systems
Breakup by Treatment Type:
- Bi-hormonal
- Insulin Only
- Hybrid
Breakup by End-User:
- Hospitals
- Medical Centres
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The competitive landscape of the industry has also been examined with some of the key players being Beta Bionics Inc., Bigfoot Biomedical Inc., Dexcom Inc., Inreda Diabetic B.V., Insulet Corporation, Johnson & Johnson, Medtronic Inc., F. Hoffmann-La Roche Ltd, Tandem Diabetes Care Inc., etc.Key Questions Answered in This Report
- How has the global artificial pancreas device systems market performed so far and how will it perform in the coming years?
- What are the key regional markets?
- What has been the impact of COVID-19 on the global artificial pancreas device systems market?
- What is the breakup of the market based on the device type?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the end-user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global artificial pancreas device systems market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Indicators
2 Scope and Methodology
4 Introduction
5 Global Artificial Pancreas Device Systems Market
6 Market Breakup by Device Type
7 Market Breakup by Treatment Type
8 Market Breakup by End-User
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Beta Bionics Inc.
- Bigfoot Biomedical Inc.
- Dexcom Inc.
- Inreda Diabetic B.V.
- Insulet Corporation
- Johnson & Johnson
- Medtronic Inc.
- F. Hoffmann-La Roche Ltd
- Tandem Diabetes Care Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 135 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 2.33 Billion |
| Forecasted Market Value ( USD | $ 5.8 Billion |
| Compound Annual Growth Rate | 10.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
